Paul L. Berns is the co-founder, Chief Executive Officer and Chairman of Neumora Therapeutics and a Managing Director with ARCH Venture Partners. Mr. Berns has been a member of ARCH Venture Partners since August 2018 and became a Managing Director in 2021. Mr. Berns is the Co-founder and Executive Chairman of both Tenvie Therapeutics and Ollin Biosciences. Mr. Berns was also the Co-founder and Chairman of the Board of Directors for HI-Bio prior to it acquisition by Biogen in July 2024, as well as a Co-founder and Lead Independent Director of Metsera Therapeutics prior to its acquisition by Pfizer in November 2025. Mr. Berns is co-founder and member of the Board of Directors of Salma Health, and currently serves as Chairman of the Board of Directors of the privately held company Happy AI, and is a member of the Board of Directors of Mirador Therapeutics, Kardigan, Rhygaze, and Epirium.
From 2014 to 2016, Mr. Berns served as President, Chief Executive Officer and Chairman of the Board of Directors at Anacor Pharmaceuticals, a biopharmaceutical company which was acquired by Pfizer in 2016. Previously, Mr. Berns served as President and Chief Executive Officer of Allos Therapeutics, a biopharmaceutical company from 2006 to 2012, when it was acquired by Spectrum Pharmaceuticals. Mr. Berns was President and Chief Executive Officer of Bone Care International, a specialty pharmaceutical company from 2002 to 2005 when it was acquired by Genzyme Corporation.
Prior to that, Mr. Berns was Vice President and General Manager of the Immunology, Oncology, and Pain Therapeutics business unit of Abbott Laboratories from 2001 to 2002, and from 2000 to 2001, he served as Vice President, Marketing of BASF Pharmaceuticals/Knoll, when it was acquired by Abbott Laboratories in 2001. Earlier in his career, Mr. Berns held various positions, including senior management roles, at Bristol-Myers Squibb (BMS) from 1990 to 2000.
Mr. Berns previously served on the Board of Directors of Areteia Therapeutics (2023-2025), EQRx (2020 to 2023), Jazz Pharmaceuticals plc (2010 to 2021), MC2 Therapeutics (2017 to 2020), Menlo Therapeutics (2017 to 2020), Unity Biotechnology (2018 to 2025), Anacor Pharmaceuticals (2012 to 2016), XenoPort (2005 to 2016), Allos Therapeutics (2006 to 2012), and Bone Care International (2002 to 2005). Mr. Berns holds a B.S. in Economics from the University of Wisconsin.
What is Paul L. Berns' net worth?
The estimated net worth of Paul L. Berns is at least $16.42 million as of February 17th, 2026. Berns owns 7,395,185 shares of Neumora Therapeutics stock worth more than $16,417,311 as of April 27th. This net worth evaluation does not reflect any other investments that Berns may own. Learn More about Paul L. Berns' net worth.
How do I contact Paul L. Berns?
Has Paul L. Berns been buying or selling shares of Neumora Therapeutics?
Paul L. Berns has not been actively trading shares of Neumora Therapeutics during the past quarter. Most recently, Paul L. Berns sold 9,819 shares of the business's stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $3.51, for a transaction totalling $34,464.69. Following the completion of the sale, the insider now directly owns 7,395,185 shares of the company's stock, valued at $25,957,099.35. Learn More on Paul L. Berns' trading history.
Who are Neumora Therapeutics' active insiders?
Are insiders buying or selling shares of Neumora Therapeutics?
In the last twelve months, Neumora Therapeutics insiders bought shares 2 times. They purchased a total of 3,831,400 shares worth more than $9,999,954.00. In the last twelve months, insiders at the sold shares 5 times. They sold a total of 138,090 shares worth more than $390,051.47. The most recent insider tranaction occured on February, 17th when insider Daljit Singh Aurora sold 6,165 shares worth more than $21,947.40. Insiders at Neumora Therapeutics own 26.8% of the company.
Learn More about insider trades at Neumora Therapeutics. Information on this page was last updated on 2/17/2026.
